Engineered B-cell Therapeutics
Innovative Cellular Immunotherapies for Persons with Solid Tumor Cancers
Innovative Cellular Immunotherapies for Persons with Solid Tumor Cancers
Bespoke Biotherapeutics was created to overcome obstacles to the effective natural immune response and limitations of currently approved immunotherapies against cancer by inventing novel, customized (i.e., bespoke) "living drugs" called engineered B-cell therapeutics.
Bespoke is built upon customized B-cell sourcing, isolation, activation, culture expansion, and non-viral genetic engineering methodologies uniquely suited to optimize commercial B-cell products for infusion.
Bespoke is focused on utilizing its platform technologies to create a pipeline of autologous and allogeneic (off-the-shelf) products that will address the physical and emotional needs of persons with solid tumor cancers.
Bespoke's innovative technology and impactful pipeline are supported by licensed and optioned intellectual property (IP) including eleven (11) granted US and three (3) granted international B-cell engineering patents plus seven (7) pending B-cell engineering patent applications. This IP position favorably positions the company and serves as a foundation upon which additional new patent applications will be generated.
Steven is a results-driven biotechnology leader and entrepreneur with over 25 years of academic and business experience, including private and public company CEO roles. He has led successful INDs, NDAs, product approvals, fundraising, and exits. Prior to industry, he held leadership clinical, science, and education roles at the Cleveland Clinic and St. Jude Children's Research Hospital.
Branden is a pioneer and expert in viral and non-viral immune cell genome engineering. He leads a robust academic research program focused on engineering B-cells and other immune cells into immunotherapies for clinical trial. He co-founded B-MoGen Biotechnologies (acquired by Bio-Techne) and Catamaran Bio, a company focused on engineered NK-cell therapies against cancer.
Kirk has over 25 years of pharmaceutical and biotechnology drug development experience, specializing in bio-manufacturing technical operations, including all aspects of chemistry, manufacturing, and controls. He has extensive FDA regulatory experience related to a broad array of personalized autologous and off-the-shelf, allogeneic cellular therapies, including CAR-T products.
Tullia is a leader in the fields of intra-tumoral B-cell function, spatial imaging, and transcriptomics. Her research lab is focused on the study of how B-cells impact T-cells in the tumor microenvironment within tumor-associated (tertiary) lymphoid structures. Tullia is an Assistant Professor of Immunology at the University of Pittsburgh
Tullia is a leader in the fields of intra-tumoral B-cell function, spatial imaging, and transcriptomics. Her research lab is focused on the study of how B-cells impact T-cells in the tumor microenvironment within tumor-associated (tertiary) lymphoid structures. Tullia is an Assistant Professor of Immunology at the University of Pittsburgh and a faculty member in the Tumor Microenvironment Center and Cancer Immunology and Immunotherapy Program at the UPMC Hillman Cancer Center. She completed her doctoral training at Johns Hopkins and post-doctoral training at the University of Colorado - both with a focus in tumor immunology. Tullia is active in the Society for Immunotherapy of Cancer and a co-organizer of the B-cells in Cancer Consortium (BC^3).
Brad is a distinguished scientist and inventor of immune-based strategies to prevent, detect, and treat cancer. His laboratory uses genomic technologies, bioinformatics, clinical specimens, and animal models to map the immune response to solid tumors such as breast, ovarian, and prostate cancers. Brad is the scientific co-director of Brit
Brad is a distinguished scientist and inventor of immune-based strategies to prevent, detect, and treat cancer. His laboratory uses genomic technologies, bioinformatics, clinical specimens, and animal models to map the immune response to solid tumors such as breast, ovarian, and prostate cancers. Brad is the scientific co-director of British Columbia's Cancer's Immunotherapy Program, Professor of Biochemistry/Microbiology at the University of Victoria, Professor of Medical Genetics at the University of British Columbia, and founding Director of the Deeley Research Centre. He completed his doctoral training at the UC Berkeley and post-doctoral training at the Fred Hutchinson Cancer Research Center. Brad is a co-organizer of BC^3 along with Tullia Bruno.
Justin is a rising star in the fields of B-cell immunology, antibody production, and B-cell engineering. His laboratory uses advanced genome editing techniques to produce engineered B-cells capable of producing protective antibodies against viral pathogens, some of which are associated with cancer development. Justin is an Associate Profe
Justin is a rising star in the fields of B-cell immunology, antibody production, and B-cell engineering. His laboratory uses advanced genome editing techniques to produce engineered B-cells capable of producing protective antibodies against viral pathogens, some of which are associated with cancer development. Justin is an Associate Professor in the Vaccine and Infectious Disease Division at Fred Hutch and an affiliate faculty member at the University of Washington. He completed his doctoral training in immunology at the University of Pennsylvania and post-doctoral training at the University of Minnesota.
Bespoke is reprogramming human, peripheral blood-derived B-cells into intuitive "living drug" immunotherapies. Our unique anti-cancer platforms, described below, involve different combinations of engineered functions in order to target the particular needs of persons with specific solid tumor cancers and specific disease stages. Engineered functions can include specific tissue homing, tumor-associated antigen binding, tumor antigen presentation to T-cells, tumor reactive antibody secretion, immunomodulatory cytokine secretion, T-cell co-stimulation, and secretion of biomarker molecules.
Cancer Sentinels are designed to seek and destroy residual and recurrent cancer cells following completion of primary surgical and adjuvant therapy in select, high-risk Stage II and Stage III solid tumor cancer patient populations. The goal is to prevent clinical relapse, especially as metastatic disease, extend survival, and mitigate the emotional distress associated with standard "watch and wait" cancer surveillance.
Cancer Rangers are designed to engage and eliminate measurable and occult cancer in select patients with metastatic solid tumor cancers. The B-cells in Cancer Rangers are engineered to provide a tumor-localized and multimodal attack on the cancer cells. Cancer Rangers are being developed as a standalone therapy and to be used in combination with other immunotherapy, such as immune checkpoint inhibitors and CAR-T.
Like autologous Cancer Rangers, described above, allogeneic Cancer Rangers are designed to address unmet needs of persons with newly diagnosed or recurrent metastatic solid tumor cancers. However, instead of being made from a patient's own B-cells, allogeneic Cancer Rangers are made from normal donor B-cells and intended for rapid, off-the-shelf use. Allogeneic Cancer Rangers can be manufactured in bulk ahead of time and stored until needed. These products are intended to benefit large populations of cancer patients with similarities between their individual cancers.
Nature 2020; 577:474-476.
Cancer Cell 2021; 39:1293-1296.
Nat Rev Cancer 2022; 22:414-430.
Sci Rep 2018;8:12144.
Sci Immunol 2019; 4:eaax0644.
Trends Mol Med 2022; 28:P528-529.
Methods Mol Biol 2020; 2115:435-444.
To learn more about Bespoke Biotherapeutics and communicate directly with a member of the company's leadership team, please use the email links below.